FDA: “Extreme” Anti-Aging Claims Led To 2012 Warning Letters
This article was originally published in The Rose Sheet
A proliferation of “extreme” anti-aging cosmetic claims that crossed the line into drug territory led to FDA’s cluster of warning letters in 2012, according to Jennifer Thomas, director of the division of enforcement in the Center for Food Safety and Applied Nutrition’s office of compliance,
You may also be interested in...
Pointing to the uptick in consumer class actions targeting cosmetics claims and the lull in FDA enforcement action in the sector since the 2012 warning-letter blitz, Arent Fox partner Georgia Ravitz speculates that the agency is “letting the marketplace now scrutinize product label claims to determine whether they’re false or misleading.”
An FDA guidance document intended to clarify if firms conducting certain drug studies involving human subjects are obligated to file Investigational New Drug Applications instead raises questions for the cosmetics industry.
An initial product featuring Living Proof’s Strateris polymer film technology, designed to combat gravity’s effect on aging skin, is slated to launch in March under a joint venture with Valeant Pharmaceuticals. The move will extend Living Proof’s portfolio beyond hair care and provide access to the physician channel.